State-of-the-art Lecture Immunotherapy: Impact from Surgeon’s Point of View – UroToday
|
State-of-the-art Lecture Immunotherapy: Impact from Surgeon's Point of View
UroToday With regards to adjuvant immunotherapy, the Immotion Trial 010 is currently recruiting for 12 months of adjuvant atezolizumab vs placebo for all renal cancer histologies (≥pT1, any T and positive N). In the neoadjuvant setting, preliminary data from a … |
